New Mission, New Website coming soon! Learn more now.

Equities logo
Close this search box.

AbbVie Partners With Genmab on Cancer Treatments, $750 Million Upfront + Up to $3.15 Billion

AbbVie is paying $750 million upfront to jointly develop and commercialize three of Genmab’s antibodies, including its blood cancer treatment candidate, epcoritamab, currently in a mid-stage study.